BioLight Life Sciences Ltd.

TASE:BOLT Stock Report

Market Cap: ₪27.6m

BioLight Life Sciences Past Earnings Performance

Past criteria checks 0/6

BioLight Life Sciences's earnings have been declining at an average annual rate of -45.2%, while the Life Sciences industry saw earnings growing at 19.8% annually. Revenues have been growing at an average rate of 2.1% per year.

Key information

-45.2%

Earnings growth rate

-44.8%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate2.1%
Return on equity-23.3%
Net Margin-3,109.6%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How BioLight Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TASE:BOLT Revenue, expenses and earnings (ILS Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-674
31 Mar 240-2464
31 Dec 230-2665
30 Sep 230-2874
30 Jun 230-2974
31 Mar 230-1074
31 Dec 220-874
30 Sep 220-774
30 Jun 220-574
31 Mar 220-374
31 Dec 210064
30 Sep 210064
30 Jun 210-174
31 Mar 210-864
31 Dec 200-1274
30 Sep 200-843
30 Jun 200-854
31 Mar 200-996
31 Dec 190-1265
30 Sep 190-13107
30 Jun 19064118
31 Mar 19364139
31 Dec 18370118
30 Sep 184651410
30 Jun 184-141312
31 Mar 181-161314
31 Dec 171-171315
30 Sep 171-211315
30 Jun 172-191313
31 Mar 172-181312
31 Dec 162-221411
30 Sep 162-211411
30 Jun 162-211411
31 Mar 162-231413
31 Dec 151-191313
30 Sep 152-201315
30 Jun 151-221316
31 Mar 151-221217
31 Dec 141-231219
30 Sep 140-221218
30 Jun 140-211118
31 Mar 140-201119

Quality Earnings: BOLT is currently unprofitable.

Growing Profit Margin: BOLT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BOLT is unprofitable, and losses have increased over the past 5 years at a rate of 45.2% per year.

Accelerating Growth: Unable to compare BOLT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BOLT is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (1.4%).


Return on Equity

High ROE: BOLT has a negative Return on Equity (-23.28%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 00:23
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioLight Life Sciences Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pooya HemamiEdison Investment Research
Brian MurphyMerriman Capital, Inc
Brian MarckxZacks Investment Research Inc.